logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics accelerating into the clinic

David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), updates Proactive London's Andrew Scott on the progress of its lead candidate SLN124  which is being developed to treat iron overload disorders.

It already has orphan drug designation in Europe and a phase Ib, first-in-human trial is scheduled to start in the third quarter.

Solomon also elaborates on two other exciting assets in the portfolio - one of them being SLN360 which is being developed as a potential treatment for cardiovascular disease.

Quick facts: Silence Therapeutics PLC

Price: 314 GBX

AIM:SLN
Market: AIM
Market Cap: £245.95 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Silence Therapeutics hits first milestone in Mallinckrodt deal

Silence Therapeutics PLC's (LON:SLN) David Solomon speaks to Proactive London's Andrew Scott soon after announcing they've hit the first milestone in their deal with Mallinckrodt Pharmaceuticals - triggering a US$2mln research payment. The UK specialist in RNA therapeutics has already...

3 weeks, 5 days ago

2 min read